Concerns & Risks -- 4/10
P/E is meaningless (AMC is loss-making: consensus FY2026 EPS -$0.25, net income -$112M). EV/EBITDA is the correct lens for a capital-intensive, levered exhibitor. P/FCF is not meaningful either -- with FY2026E free cash flow still likely negative, it is n/m, which is itself the most damning read on a name whose entire problem is that EBITDA does not convert to cash.
| Metric (FY2026E) | AMC Multiple | Peer Avg (Cinemark) |
|---|---|---|
| EV/EBITDA -- corporate-debt basis | ~5.4x | ~6.9x (2026E) |
| EV/EBITDA -- total-debt basis (incl. finance + lease) | ~10.3x | ~6.9x (2026E) |
| P/Sales | ~0.23x | ~1.0x+ |
| P/FCF | n/m (FCF negative) | Positive FCF |
| # | Catalyst | Detail |
|---|---|---|
| 1 | 2026 Box-Office Recovery (in motion) | NA Q1 2026 box office +22% YoY; Q1 adj. EBITDA $38.3M a post-pandemic Q1 record (+$96M YoY). Mgmt guides 2026 box office +$500M to +$1.2B vs 2025. The live, credible catalyst. |
| 2 | Theatrical-Window Extension | Universal and Paramount publicly committing to 45-day exclusive windows; Disney constant. Restores exhibitor economics. |
| 3 | Netflix Theatrical (Narnia, Feb 2027) | 49-day window -- first major Netflix theatrical release, a potential new content pipeline. |
| 4 | Arena 1 at AMC (June 2026 launch) | Live-concert rev-share product across 300+ US locations and ~260 Odeon screens, near-zero upfront capex. Optionality, unproven economics. |
| 5 | Deleveraging (ongoing) | $155.8M debt-to-equity convert; $400M→$425M refinance pushing 2027 maturities to 2031; covenant step-downs on ~$2.9B of debt as leverage falls. |
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | Chronic Equity Dilution | HIGH | AMC funds itself via an ATM equity program ($72M raised in Q1) and debt-to-equity conversions, so existing holders face relentless share-count growth that caps per-share upside. |
| 2 | Balance-Sheet Fragility | HIGH | Net-debt/EBITDA ~5.7x, total-debt/EBITDA ~19.7x -- no margin for a soft slate year. GAAP-unprofitable through 2028 on consensus. |
| 3 | Streaming / Window Compression | MEDIUM | Secular substitution threat -- mitigating, not worsening, in 2026 as windows lengthen, but the structural pressure remains. |
| 4 | FX / International | MEDIUM | European (Odeon) results carry FX swing (Q1 2026 ~10.8% FX tailwind). No Chinese regulatory/demand risk. |
| 5 | Direct Regulatory Overhang | LOW | Low direct regulatory risk. Labor risk eased (multi-year SAG-AFTRA and WGA deals signed). |
Score of 4/10 reflects a mixed risk profile that lands squarely in the middle-to-below-middle of the rubric. AMC earns credit on two legs but loses heavily on the rest.
What supports the score: Zero China exposure -- US-domestic + European (Odeon), no Chinese regulatory/demand risk (+). A genuine, in-motion near-term catalyst -- the 2026 box-office recovery, window-lengthening, and the Arena 1 launch (+). Best-in-class premium footprint and real operating leverage inflecting off a strike-depressed trough (+).
Why not higher: Misleading valuation -- superficially cheap on corporate-debt EV/EBITDA (~5.4x) but at-to-above peer (~10x) once the full ~$7.9B total debt/lease load is included, against a peer that is both cheaper on quality-adjusted terms and far healthier (-). Balance-sheet fragility -- ~5.7x net leverage, no GAAP profitability through 2028, and chronic equity dilution that caps per-share upside (-). The catalysts accrue disproportionately to the enterprise's creditors and to the healthier peer.
Net: AMC is the higher-beta, lower-quality way to express the box-office recovery thesis. Mixed catalysts + at/above-peer quality-adjusted valuation + a leverage overhang = 4/10. Cinemark expresses the identical recovery with real net income and a far healthier balance sheet.